Filtered By:
Condition: Antiphospholipid Syndrome
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 523 results found since Jan 2013.
Ischemic stroke due to carotid artery stenosis in a patient with Hughes Syndrome
Can J Neurol Sci. 2023 May 9:1-5. doi: 10.1017/cjn.2023.57. Online ahead of print.NO ABSTRACTPMID:37158219 | DOI:10.1017/cjn.2023.57
Source: The Canadian Journal of Neurological Sciences - May 9, 2023 Category: Neurology Authors: Yanli Du Siyang Zheng Hui Qi Zongli Han Source Type: research
Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
ConclusionAdditional detection of non-criteria aPLs including aPC IgG/M, aPE IgG/M/A, aPI IgG/M, aSM IgG/M, and aPA IgG/M could assist in APS diagnosis. The positivity of certain aPLs was statistically associated with both criteria and extra-criteria APS clinical manifestations.
Source: Frontiers in Immunology - April 12, 2023 Category: Allergy & Immunology Source Type: research
Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch
Lupus. 2023 Mar 20:9612033231165151. doi: 10.1177/09612033231165151. Online ahead of print.ABSTRACTCerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic events tend to occur in patients with SLE at a higher frequency when Antiphospholipid antibodies (aPLs) are present, and tend to involve the large cerebral vessels. The mechanism of stroke in SLE can be driven by complement deposition and neuroinflammation involving the blood-brain barrier although the traditional cardiovascular ri...
Source: Lupus - March 20, 2023 Category: Rheumatology Authors: Georges El Hasbani Imad Uthman Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation
ConclusionsThis study demonstrates the presence of aPLs in a subgroup of COVID-19 patients who presented AIS, suggesting a role in the mechanisms contributing to hypercoagulable state in these patients. Detecting these antibodies as a serological marker to check and monitor COVID-19 may contribute to improve the risk stratification of thromboembolic manifestations in these patients.
Source: Frontiers in Immunology - March 2, 2023 Category: Allergy & Immunology Source Type: research
Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome
Antiphospholipid syndrome (APS) – as included in the updated APS classification criteria – is characterized by circulating antibodies (Abs) directed against phospholipid-binding proteins or their complex with phospholipids (aPL) and clinical manifestations of thrombosis or gestational morbidity.1 These criteria are very specif ic to ensure homogeneity for some purposes, such as clinical assays, yet they are not very sensitive for APS diagnosis.2 Due to this lack of sensitivity, clinicians must be aware of some entities – distinct from thrombosis fetal losses, or eclampsia – that are not included in the classificati...
Source: Journal of Stroke and Cerebrovascular Diseases - February 24, 2023 Category: Neurology Authors: Miguel Ángel Estévez, Nallibe Lanio, Águeda Molina, Maria Reyes Jiménez-León, María José Picado, Eva Esteban, Sonia Sánchez, Lucio Pallarés, Maria Rosa Julià Source Type: research
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thrombosis and/or pregnancy morbidity related to the presence of persistent antiphospholipid autoantibodies (aPL) [1]. The most frequent clinical manifestations of APS are thrombotic events and death may be caused by stroke, myocardial infarction, pulmonary embolism or catastrophic APS [2]. APS treatment is based on long term anticoagulation [3].
Source: Thrombosis Research - February 9, 2023 Category: Hematology Authors: Thomas Ballul, Arthur Mageau, Pascale Roland Nicaise, Nadine Ajzenberg, Andrey Strukov, Antoine Dossier, Diane Rouzaud, Thomas Papo, Karim Sacr é Tags: Letter to the Editors-in-Chief Source Type: research
What you need to know about migraine in Hughes syndrome patients
CONCLUSION: Most neurologists don't see or recognize many aPL-positive patients in their practice, so hematologists and rheumatologists who see these patients should recognize that refractory headache may be a manifestation of their immune-mediated hypercoagulable disorder and understand that the potential risks of not addressing this issue may be high.PMID:36708185 | DOI:10.1177/09612033231153790
Source: Lupus - January 28, 2023 Category: Rheumatology Authors: J R Schofield K L Hassell Source Type: research
SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis
We present systemic lupus erythematosus (SLE) as a model rheumatic disease with endothelial dysfunction and discuss its mechanisms, factors that influence the early onset and rapid progression of atherosclerosis, and the increased risk of thromboembolic events. We focus on established methods to improve endothelium function, including statins, antiplatelet, and antithrombotic therapy. Hypercoagulable and hypofibrinolitic states and a hyperinflammatory response characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several pathogenic mechanisms are typical for an acute phase of Covid-19 post-Co...
Source: Atherosclerosis - January 9, 2023 Category: Cardiology Authors: Wojciech P łazak Leszek Drabik Source Type: research
Primary antiphospholipid syndrome in a male with myocardial infarction with non-obstructive coronary arteries and a history of stroke
Kardiol Pol. 2022 Dec 22. doi: 10.33963/KP.a2022.0295. Online ahead of print.NO ABSTRACTPMID:36546600 | DOI:10.33963/KP.a2022.0295
Source: Polish Heart Journal - December 22, 2022 Category: Cardiology Authors: Pawe ł Rostoff Dominika Drwi ła-Stec Krzysztof Karwat Ma łgorzata Urbańczyk-Zawadzka Jadwiga Nessler Ewa Konduracka Source Type: research
